Last close As at 05/08/2026
JPY3,549.00
▲ 86.00 (2.48%)
Market capitalisation
JPY9,205m
Research: TMT
Dentsu’s FY23 net revenue was a touch above guidance at Q3, with a better-than-expected operating margin reflecting a good Q4 in Japan, further boosted by a short delay in an IT project pushed out to Q124. The results were accompanied by the news of a change in global CFO, with the role reverting to Yushin Soga, who held the role until January 2023. As anticipated, net revenue outside Japan declined, although there was some trading improvement in the US in Q4. A thorough business review is now in progress, with the next mid-term plan due early in H2. In the meantime, the balance sheet is strong, with leverage reduced to 0.6x EBITDA, and share buybacks will be resumed. We regard the rating as undemanding.
Dentsu |
Return to organic growth forecast for FY24 |
FY23 results |
Media |
20 February 2024 |
Share price performance
Business description
Next events
Analysts
Dentsu is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||||||||||||||||||||||
Dentsu’s FY23 net revenue was a touch above guidance at Q3, with a better-than-expected operating margin reflecting a good Q4 in Japan, further boosted by a short delay in an IT project pushed out to Q124. The results were accompanied by the news of a change in global CFO, with the role reverting to Yushin Soga, who held the role until January 2023. As anticipated, net revenue outside Japan declined, although there was some trading improvement in the US in Q4. A thorough business review is now in progress, with the next mid-term plan due early in H2. In the meantime, the balance sheet is strong, with leverage reduced to 0.6x EBITDA, and share buybacks will be resumed. We regard the rating as undemanding.
Year end |
Net revenue (¥bn) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/21 |
976.6 |
146.0 |
392 |
118 |
10.3 |
2.9 |
12/22 |
1,119.5 |
187.6 |
488 |
155 |
8.3 |
3.8 |
12/23 |
1,129.5 |
151.3 |
340 |
140 |
11.9 |
3.4 |
12/24e |
1,189.3 |
159.8 |
382 |
140 |
10.6 |
3.4 |
12/25e |
1,227.0 |
178.7 |
406 |
141 |
10.0 |
3.4 |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Headwinds look to be easing
A number of the headwinds that troubled the group in FY23 should ease in FY24, with management guiding to organic revenue growth of 1%, and progress weighted to H2. In North America, H1 results will continue to be affected by earlier client losses but, encouragingly, there are signs of a resurgence in tech client spend and an improving new business win rate, with average project size picking up. Asia-Pacific is the most problematic region, and ¥53.1bn of intangibles has been written off. Across the group, the dismantling of silos under the One dentsu project is bringing together the skill sets in consulting, technology, media and creative. Adjusted operating margin for FY24 is guided to 15.1% (FY23: 14.5%, 16.1% excluding the impact of the DACH cluster issue and severance), reflecting continuing internal investment in data and technology as well as in people and skills. We have adjusted our estimates to bring them closer to guidance.
Focus on shareholder returns
The stronger balance sheet, with FY23 net debt/EBITDA of 0.59x (below 1.0–1.5x guidance), has enabled a higher dividend payout ratio and the reinstatement of the share buyback programme for FY24. Dentsu is setting up a new advisory finance committee to help boost shareholder returns through improved profitability and conversion to cash – core objectives for the next medium-term management plan.
Valuation: Not demanding
Dentsu’s share price is up 11% year-to-date, while global marketing service group peers have gained an average of 7%, albeit with divergent performances. Dentsu’s shares trade well below their long-term average of 1.4x EV/net revenue and at a 27% discount to peers on average FY23–25e EV/EBITDA.
Concerted efforts to shift the dial
Dentsu’s mid-term targets for FY21–24 for organic revenue growth of 4–5% CAGR, an operating margin of 17.0–18.0% in FY23 and 18.0% in FY24 will obviously not now be met, although this has been apparent for some time. This is due to a combination of internal and external factors, and the new mid-term growth plan currently being worked on should address the core issues, which we view as the need to strengthen the core business offering, simplify the organisation and invest in data and technology. The focus of the plan is on improving the returns to shareholders, through driving growth and cash conversion.
The One dentsu initiative is central to driving improved revenue and margin performance and has resonance with realignments taking place across the peer set. The need for systems and data to be readily available to structure and inform projects should mean greater coherence in the offering, giving more holistic solutions to client business challenges, rather than each agency approaching separately with their own skill sets on offer (‘Integrated Growth Solutions’ in Dentsu’s vernacular). Pooled specialist resources can deliver more efficiently with better utilisation rates. This is taken further by the identification of accelerator clients, of which there are currently 11 with multinational footprints, each with account leads working closely with the client. 30 further regionally strategic clients have been identified, which will benefit from the One dentsu approach and may become accelerator clients over time.
The scale of the global operations can make it difficult to adjust quickly, with the poor economic backdrop accentuating the weak points. Addressing the problems in the Asia-Pacific region is clearly a short-term priority and the impairment loss of ¥53.1bn (of which goodwill represents 95%) acknowledges this.
Exhibit 1: Summary of revisions to forecasts
Net revenue (¥bn) |
Adjusted operating profit (¥bn) |
EPS (¥) |
|||||||
Old |
New |
% chg. |
Old |
New |
% chg. |
Old |
New |
% chg. |
|
2023 |
1,122.3 |
1,129.5 |
+1 |
151.5 |
163.5 |
+8 |
335 |
340 |
+1 |
2024e |
1,172.6 |
1,189.3 |
+1 |
180.7 |
180.0 |
u/c |
436 |
382 |
-13 |
2025e |
1,213.6 |
1,227.0 |
+1 |
199.3 |
196.0 |
-2 |
650 |
406 |
-38 |
Source: Dentsu accounts, Edison Investment Research. Note: 2023 ‘Old’ = prior estimates.
Our revised forecasts for the current year are set to match the current company guidance, which we regard as sensible. Given the commentary around the FY23 figures and outlook, the likelihood is that the results will be weighted to H2.
We have made modest consequent adjustments to our FY25 figures and acknowledge the obvious gremlin that had slipped through on the EPS figure. 6% year-on-year progress looks more reasonable, helped by the continuation of the share buyback programme.
|
Exhibit 2: Long-term regional net revenue and operating margin performance |
|
|
Source: Denstu accounts, Edison Investment Research |
We may be overly cautious on the timing of the likely improvement in adjusted operating margin, given that the earlier ambition was for 18.0%, but the outlook here should be clearer once details of the next mid-term plan are disseminated.
Japan delivers best regional performance
Japan (40% FY23 net revenue): Q4 organic net revenue growth 0.9%, FY23 organic growth 1.6%.
The group’s Japanese business is demonstrating the benefits of the concentration on Customer Transformation & Technology (CT&T), now 30.8% of regional revenues, up from 28.2% in FY22. The ability to bring creative expertise into the consultancy offering is opening additional opportunities and driving growth, despite the relative weakness of the TV advertising market. The stronger-than-expected operating margin performance (FY23: 23.0%) partly reflects this business mix and partly the delay from November until February 2024 of an IT upgrade project.
The FY24 outlook for the Japanese business is described as ‘robust’.
Americas (28.7% FY23 net revenue): Q4 organic net revenue decline -9.3%, FY23 organic decline -7.2%.
FY23 performance was affected by the well-documented reduction in spend by major tech and finance clients on both marketing and transformation projects, so affecting revenues in both Media and CT&T. Creative actually posted a small positive organic growth rate of 1% for the year. Dentsu also suffered some client losses, the impact of which will extend into H124. The roll-out of One dentsu is clearly having a positive impact, with higher win conversion rates and better client retention.
Management reports some resumption of spend by tech clients in Q423, which has extended into Q124, giving hope for better full-year prospects. Lead times remain slow but the pipeline is good, and, encouragingly, is 90% offensive, whereas this time last year the figure was 60%.
EMEA (21.2% FY23 net revenue): Q4 organic net revenue decline -13.6%, FY23 organic decline 10.9%.
There were a number of factors behind the poor performance in the EMEA region. Firstly, there was a pattern of reduced media spending in technology and finance, measured against strong prior year comparators. Secondly, as in the Americas, CT&T declined after client losses in H123 with slower pipeline conversion and reduced project scope from several clients. Patterns by country across the region were mixed, with positive organic growth in Spain and Italy, and generally better local performance than that from global accounts.
The issue on a highly complex set of interwoven projects in business transformation and systems integration across the DACH region that was identified late in Q223 carried across into Q323 as more remedial work was done. No further adjustments were needed in Q423. This issue alone is estimated by management to have cost a 100bp reduction in the group FY23 operating margin.
New regional management is now in place, tasked with rolling out the integrated growth solutions approach, backed by the One dentsu initiative.
Asia-Pacific (excluding Japan) (10.1% FY23 net revenue): Q4 organic net revenue decline 8.6%, FY23 organic decline -8.2%.
The Asia-Pacific region experienced challenging macroeconomic conditions in many of the individual territories. This played out in lower Media revenues across the region as clients pulled back spend, with Creative organic revenues declining on weakness in China, although South Korea and Hong Kong largely bucked the trend. India also suffered from Media client losses in Q223 and reduced project spend, particularly in CT&T.
The plan for driving growth and recovery in the region focuses on:
■
rebuilding the core businesses in China, Australia and New Zealand, and India, with roll-out of best practice from across the region and the wider group;
■
strengthening delivery of integrated growth solutions to accelerator clients, plus focus on Japanese clients operating in the wider Asia-Pacific region; and
■
reviewing the regional cost structure.
Valuation
We look at the valuation of Dentsu in comparison to the core set of global peers. Here Publicis has clearly been outperforming the pack both operationally and in terms of share price performance, and we also note the strong share price performance of Japan-based Hakuhodo. Dentsu’s share price is up by 11% year-to-date, with these results not providing any major surprises.
When we last carried out this exercise in November, Dentsu’s valuation was sitting at an average 33% discount in EV/EBITDA across the years CY22–24. We have now rolled this forward by a year and the average discount now sits at 27%. We would expect this discount to narrow as the benefits of the internal investment start to come through and the prospects for improving group performance by implementation of the new mid-term plan come into better focus.
Exhibit 3: Peer comparison
|
Price |
Market cap |
Share price perf YTD |
EV/revenue (x) |
EV/EBITDA (x) |
P/E (x) |
Dividend yield |
||||
Company |
(local CCY) |
(US$m) |
(%) |
CY24 |
CY23 |
CY24 |
CY25 |
CY23 |
CY24 |
CY25 |
(%) |
Publicis |
€97 |
25,417 |
16 |
1.8 |
8.6 |
8.2 |
7.9 |
13.3 |
12.7 |
11.9 |
3.6 |
Omnicom |
US$85 |
17,090 |
-3 |
1.2 |
7.4 |
7.1 |
6.7 |
11.0 |
10.2 |
9.4 |
3.5 |
Interpublic |
US$32 |
12,140 |
-3 |
1.4 |
7.8 |
7.5 |
7.2 |
11.1 |
10.4 |
9.7 |
4.1 |
WPP |
767p |
10,231 |
2 |
1.1 |
6.8 |
6.8 |
6.5 |
8.2 |
8.1 |
7.6 |
5.1 |
Hakuhodo |
¥1,343 |
3,474 |
24 |
0.4 |
8.5 |
7.4 |
6.8 |
33.0 |
20.4 |
18.5 |
2.4 |
Peer average |
|
7 |
1.2 |
7.8 |
7.4 |
7.0 |
15.3 |
12.4 |
11.4 |
3.7 |
|
Dentsu |
¥4,109 |
7,213 |
11 |
0.9 |
6.1 |
5.2 |
4.9 |
11.9 |
10.6 |
10.0 |
3.5 |
Premium/(disc.) |
|
4% |
-26% |
-22% |
-29% |
-31% |
-22% |
-14% |
-13% |
-7% |
|
Source: Refinitiv. Note: Prices at 14 February 2024.
Exhibit 4: Financial summary
¥'m |
2021 |
2022 |
2023 |
2024e |
2025e |
||
Year end 31 December |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
INCOME STATEMENT |
|||||||
Revenue |
|
|
1,085,592 |
1,243,883 |
1,289,301 |
1,356,700 |
1,393,000 |
Cost of Sales |
(109,015) |
(124,383) |
(159,786) |
(167,400) |
(166,000) |
||
Net revenue |
976,577 |
1,119,500 |
1,129,515 |
1,189,300 |
1,227,000 |
||
EBITDA |
|
|
196,917 |
217,500 |
175,742 |
203,377 |
218,527 |
Operating profit (before amort. and excepts.) |
|
|
179,028 |
204,300 |
163,515 |
180,000 |
196,040 |
Amortisation of acquired intangibles |
(29,409) |
(28,721) |
(30,600) |
(36,689) |
(36,689) |
||
Exceptionals |
93,579 |
(56,849) |
(88,065) |
(6,111) |
0 |
||
Share-based payments |
0 |
0 |
(500) |
0 |
0 |
||
Reported operating profit |
241,841 |
118,728 |
45,300 |
135,422 |
159,350 |
||
Net Interest |
(35,491) |
(20,246) |
(15,901) |
(23,664) |
(20,820) |
||
Joint ventures & associates (post tax) |
2,483 |
(1,932) |
3,400 |
3,468 |
3,521 |
||
Exceptionals |
0 |
5,467 |
301 |
0 |
0 |
||
Profit Before Tax (norm) |
|
|
146,020 |
187,589 |
151,315 |
159,804 |
178,741 |
Profit Before Tax (reported) |
|
|
208,833 |
102,019 |
33,100 |
115,225 |
142,052 |
Reported tax |
(93,979) |
(34,982) |
(38,500) |
(48,325) |
(49,718) |
||
Profit After Tax (norm) |
116,255 |
139,930 |
95,165 |
101,000 |
112,969 |
||
Profit After Tax (reported) |
114,853 |
67,036 |
(5,400) |
66,900 |
92,334 |
||
Minority interests |
(6,463) |
(6,077) |
(5,200) |
(5,200) |
(5,200) |
||
Discontinued operations |
0 |
0 |
0 |
0 |
0 |
||
Net income (normalised) |
109,203 |
130,835 |
89,800 |
101,034 |
107,769 |
||
Net income (reported) |
108,389 |
60,958 |
(10,700) |
61,700 |
87,134 |
||
Average Number of Shares Outstanding (m) |
279 |
268 |
264 |
265 |
266 |
||
EPS - normalised (¥) |
|
|
392 |
488 |
340 |
382 |
406 |
EPS - normalised fully diluted (¥) |
|
|
390 |
485 |
337 |
380 |
403 |
EPS - basic reported (¥) |
|
|
389 |
227 |
(20) |
273 |
347 |
Dividend (¥) |
118 |
155 |
140 |
140 |
141 |
||
Net revenue growth (%) |
16.9 |
14.6 |
0.9 |
5.3 |
3.2 |
||
EBITDA Margin to revenue less pass-through costs (%) |
20.2 |
19.4 |
15.6 |
17.1 |
17.8 |
||
Normalised op. margin to revenue less pass-through costs (%) |
18.3 |
18.2 |
14.5 |
15.1 |
16.0 |
||
BALANCE SHEET |
|||||||
Fixed Assets |
|
|
1,377,417 |
1,423,928 |
1,465,069 |
1,465,954 |
1,449,839 |
Intangible Assets |
858,748 |
962,100 |
1,069,800 |
1,053,562 |
1,020,324 |
||
Tangible Assets |
173,681 |
168,859 |
173,286 |
190,409 |
207,532 |
||
Investments & other |
344,988 |
292,969 |
221,983 |
221,983 |
221,983 |
||
Current Assets |
|
|
2,343,115 |
2,317,496 |
2,243,566 |
2,402,595 |
2,531,965 |
Stocks |
20,661 |
3,670 |
5,253 |
5,504 |
5,458 |
||
Debtors |
1,500,020 |
1,578,922 |
1,684,039 |
1,765,568 |
1,812,808 |
||
Cash & cash equivalents |
723,541 |
603,740 |
423,112 |
500,361 |
582,537 |
||
Other |
98,893 |
131,164 |
131,162 |
131,162 |
131,162 |
||
Current Liabilities |
|
|
(1,971,873) |
(2,017,695) |
(2,026,316) |
(2,149,422) |
(2,164,761) |
Creditors |
(1,465,110) |
(1,532,591) |
(1,578,952) |
(1,672,644) |
(1,717,397) |
||
Tax and social security |
(60,960) |
(30,894) |
(30,894) |
(30,894) |
(30,894) |
||
Short term borrowings |
(93,067) |
(95,790) |
(95,790) |
(95,790) |
(95,790) |
||
Other |
(352,736) |
(358,420) |
(320,680) |
(350,094) |
(320,680) |
||
Long Term Liabilities |
|
|
(839,188) |
(768,403) |
(671,658) |
(865,087) |
(859,470) |
Long term borrowings |
(486,122) |
(436,639) |
(431,022) |
(425,405) |
(419,788) |
||
Other long term liabilities |
(353,066) |
(331,764) |
(240,636) |
(439,682) |
(439,682) |
||
Net Assets |
|
|
909,471 |
955,326 |
1,010,661 |
854,040 |
957,573 |
Minority interests |
(64,440) |
(75,060) |
(71,100) |
(76,300) |
(81,500) |
||
Shareholders' equity |
|
|
845,031 |
880,266 |
939,561 |
777,740 |
876,073 |
CASH FLOW |
|||||||
Operating Cash Flow |
283,709 |
176,189 |
109,477 |
211,092 |
237,918 |
||
Working capital |
69,156 |
(3,519) |
(60,339) |
11,912 |
(2,440) |
||
Exceptional & other |
(98,761) |
40,156 |
83,563 |
6,803 |
(1,095) |
||
Tax |
(103,813) |
(115,764) |
(47,600) |
(48,325) |
(49,718) |
||
Net operating cash flow |
|
|
150,291 |
97,062 |
85,100 |
181,482 |
184,665 |
Capex |
318,135 |
(4,585) |
(27,600) |
(27,600) |
(27,600) |
||
Acquisitions/disposals |
(49,671) |
(40,873) |
(148,900) |
(11,487) |
(10,762) |
||
Net interest |
(14,920) |
(18,301) |
(15,901) |
(23,664) |
(20,820) |
||
Equity financing |
(30,010) |
(40,006) |
0 |
0 |
0 |
||
Net dividends |
(19,128) |
(37,895) |
(42,000) |
(35,462) |
(37,285) |
||
Other |
(147,241) |
(24,920) |
(11,574) |
0 |
0 |
||
Net Cash Flow |
207,456 |
(69,518) |
(160,874) |
83,268 |
88,199 |
||
Opening net debt/(cash) |
|
|
54,115 |
(144,352) |
(71,311) |
103,700 |
20,834 |
FX |
23,095 |
13,932 |
(11,000) |
0 |
0 |
||
Other non-cash movements |
(32,082) |
(17,455) |
(3,137) |
(402) |
(405) |
||
Closing net debt/(cash) |
|
|
(144,352) |
(71,311) |
103,700 |
20,834 |
(66,959) |
Source: Company reports, Edison Investment Research
|
|
Research: Healthcare
Ultimovacs has been granted Orphan Drug designation (ODD) from the European Medicines Agency (EMA) for UV1 in mesothelioma, marking another step forward for the clinical development of its lead universal, off-the-shelf cancer vaccine. This encouraging regulatory designation follows on the heels of the FDA ODD (October 2023) and Fast Track designation (February 2024) for UV1 in this same indication, which helps set the foundation for a potential Phase III programme. A key benefit of EU ODD is the potential for 10-year market exclusivity, provided UV1 achieves regulatory approval. The EMA decision was based on the recent positive data from the Phase II NIPU trial (reported October 2023) demonstrating a 27% reduction in risk of death with UV1 treatment compared to the standard of care in patients with malignant pleural mesothelioma (MPM). We await the results from the Phase II INITIUM trial in malignant melanoma (MM), the company’s lead indication, in March 2024, which is likely the next catalyst for the company.